Glucagon receptor antagonism induces increased cholesterol absorption
Open accessThe DOI matches its Crossref record; 55 of the 56 references it cites were found in a registry or an index.
Abstract
Glucagon and insulin have opposing action in governing glucose homeostasis. In type 2 diabetes mellitus (T2DM), plasma glucagon is characteristically elevated, contributing to increased gluconeogenesis and hyperglycemia. Therefore, glucagon receptor (GCGR) antagonism has been proposed as a pharmacologic approach to treat T2DM. In support of this concept, a potent small-molecule GCGR antagonist (GRA), MK-0893, demonstrated dose-dependent efficacy to reduce hyperglycemia, with an HbA1c reduction of 1.5% at the 80 mg dose for 12 weeks in T2DM. However, GRA treatment was associated with dose-dependent elevation of plasma LDL-cholesterol (LDL-c). The current studies investigated the cause for increased LDL-c. We report findings that link MK-0893 with increased glucagon-like peptide 2 and cholesterol absorption. There was not, however, a GRA-related modulation of cholesterol synthesis. These findings were replicated using structurally diverse GRAs. To examine potential pharmacologic mitigation, coadministration of ezetimibe (a potent inhibitor of cholesterol absorption) in mice abrogated the GRA-associated increase of LDL-c. Although the molecular mechanism is unknown, our results provide a novel finding by which glucagon and, hence, GCGR antagonism govern cholesterol metabolism.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Following 68 weeks of treatment, semaglutide impressively lowered body weight in non-diabetic, obese individuals by 14.9%, relative to 2.4% in placebo-treated controls68.”
From Transforming obesity: The advancement of multi-receptor drugs (2024) · cites this paper as [68]
Citations
Cites
A SIMPLE METHOD FOR THE ISOLATION AND PURIFICATION OF TOTAL LIPIDES FROM ANIMAL TISSUES
Folch, J., Lees, M., & Stanley, G. H. S. (1957) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)64849-5 · Cited by 65,189
Colhoun, H. M., Betteridge, D. J., Durrington, P. N., Hitman, G. A., W Neil, H. A., Livingstone, S. J., Thomason, M. J., Mackness, M. I., Charlton-Menys, V., & Fuller, J. H. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16895-5 · Cited by 3,755
Role of LXRs in control of lipogenesis
Schultz, J. R., Tu, H., Luk, A., Repa, J. J., Medina, J. C., Li, L., Schwendner, S., Wang, S., Thoolen, M., Mangelsdorf, D. J., et al. (2000) · Genes & Development · doi:10.1101/gad.850400 · Cited by 1,499
Self-citationInduction of intestinal epithelial proliferation by glucagon-like peptide 2.
Drucker, D. J., Erlich, P., Asa, S. L., & Brubaker, P. L. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.15.7911 · Cited by 880
Bolen, S., Feldman, L., Vassy, J., Wilson, L., Yeh, H.-C., Marinopoulos, S., Wiley, C., Selvin, E., Wilson, R., Bass, E. B., et al. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-147-6-200709180-00178 · Cited by 823
Glucagonocentric restructuring of diabetes: A pathophysiologic and therapeutic makeover
Unger, R. H., & Cherrington, A. D. (2012) · Journal of Clinical Investigation · doi:10.1172/jci60016 · Cited by 670
Abnormal Alpha-Cell Function in Diabetes: Response to Carbohydrate and Protein Ingestion
Müller, W. A., Faloona, G. R., Aguilar-Parada, E., & Unger, R. H. (1970) · New England Journal of Medicine · doi:10.1056/nejm197007162830301 · Cited by 626
Davis, H. R., Zhu, L.-J., Hoos, L. M., Tetzloff, G., Maguire, M., Liu, J., Yao, X., Iyer, S. P. N., Lam, M.-H., Lund, E. G., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m405817200 · Cited by 615
Self-citationGelling, R. W., Du, X. Q., Dichmann, D. S., Rømer, J., Huang, H., Cui, L., Obici, S., Tang, B., Holst, J. J., Fledelius, C., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0237106100 · Cited by 563
Human Insulin Resistance Is Associated With Increased Plasma Levels of 12α-Hydroxylated Bile Acids
Haeusler, R. A., Astiarraga, B., Camastra, S., Accili, D., & Ferrannini, E. (2013) · Diabetes · doi:10.2337/db13-0639 · Cited by 444
Research works printed but not linked: 6
- Engel, 2011, Efficacy and tolerability of MK-0893, a glucagon receptor antagonist (GRA), in patients with type 2 diabetes (T2DM), Diabetes., 60, A85
- Engel, 2012, Glycemic and lipid effects of the short-acting glucagon receptor antagonist MK-3577 in patients with type 2 diabetes, Diabetes., 61, A266
- Kazda, 2013, The glucagon receptor antagonist LY2409021 significantly lowers HbA1c and is well tolerated in patients with type 2 diabetes mellitus: a 24-week phase 2 study, Diabetologia., 56, S391
- Morgan, 2014, ISIS-GCGRRX, an antisense glucagon receptor antagonist, caused rapid, robust, and sustained improvements in glycemic control without changes in BW, BP, lipids, or hypoglycemia in T2DM patients on stable metformin therapy, Diabetes., 63, LB28
- Engel, 2011, Efficacy and safety of the glucagon receptor antagonist, MK-0893, in combination with metformin or sitagliptin in patients with type 2 diabetes mellitus, Diabetologia., 54, S86
- Drucker, 2001, Glucagon-like peptide 2, J. Clin. Endocrinol. Metab., 86, 1759
Cited by
Regulation of hepatic glucose metabolism in health and disease
Petersen, M. C., Vatner, D. F., & Shulman, G. I. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2017.80 · Cited by 1,133
The New Biology and Pharmacology of Glucagon
Müller, T. D., Finan, B., Clemmensen, C., DiMarchi, R. D., & Tschöp, M. H. (2017) · Physiological Reviews · doi:10.1152/physrev.00025.2016 · Cited by 419
“The most common associated effects in the preclinical studies are the development of hyperglucagonemia and increased -cell proliferation, but there is also preclinial and clinical evidence indicating that GcGR antagonism may increase plasma levels of total and LDL cholesterol (245, 342).”
BackgroundTargeting hepatic glucose metabolism in the treatment of type 2 diabetes
Rines, A. K., Sharabi, K., Tavares, C. D. J., & Puigserver, P. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.151 · Cited by 375
A large electronic-health-record-based genome-wide study of serum lipids
Hoffmann, T. J., Theusch, E., Haldar, T., Ranatunga, D. K., Jorgenson, E., Medina, M. W., Kvale, M. N., Kwok, P.-Y., Schaefer, C., Krauss, R. M., et al. (2018) · Nature Genetics · doi:10.1038/s41588-018-0064-5 · Cited by 297
“Although a role for the pancreas in LDL-metabolism has not been established, glucagon, a hormone synthesized in pancreatic islet alpha cells, has been reported to decrease intestinal cholesterol absorption 59 .”
The Role of Glucagon in the Pathophysiology and Treatment of Type 2 Diabetes
Hædersdal, S., Lund, A., Knop, F. K., & Vilsbøll, T. (2018) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2017.12.003 · Cited by 162
“Glucagon receptor antagonists have been associated with increased cholesterol absorption from the gut.(218)”
BackgroundGlucagon Regulation of Energy Expenditure
Kleinert, M., Sachs, S., Habegger, K. M., Hofmann, S. M., & Müller, T. D. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20215407 · Cited by 147
“However adverse effects such as increased hepatic fat accumulation and increased LDL cholesterol have been reported for these antagonists in humans [20,21].”
BackgroundThe α-cell in diabetes mellitus
Gromada, J., Chabosseau, P., & Rutter, G. A. (2018) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0097-y · Cited by 143
Transforming obesity: The advancement of multi-receptor drugs
Kusminski, C. M., Perez-Tilve, D., Müller, T. D., DiMarchi, R. D., Tschöp, M. H., & Scherer, P. E. (2024) · Cell · doi:10.1016/j.cell.2024.06.003 · Cited by 126
GLP-1 physiology in obesity and development of incretin-based drugs for chronic weight management
Holst, J. J. (2024) · Nature Metabolism · doi:10.1038/s42255-024-01113-9 · Cited by 125
“Also, cholesterol metabolism may be perturbed 191 .”
Kim, T., Nason, S., Holleman, C., Pepin, M., Wilson, L., Berryhill, T. F., Wende, A. R., Steele, C., Young, M. E., Barnes, S., et al. (2018) · Diabetes · doi:10.2337/db17-1502 · Cited by 97
“BAs are ligands of the FXR (FXR/Nr1h4) (15), leading us to investigate FXR signaling in glucagon action.”
BackgroundInfluentialClinical Trials, Triumphs, and Tribulations of Glucagon Receptor Antagonists
Pearson, M. J., Unger, R. H., & Holland, W. L. (2016) · Diabetes Care · doi:10.2337/dci15-0033 · Cited by 90
“cholesterol absorptionwhile lowering blood glucose (21).”
New Insights into Beta-Cell GLP-1 Receptor and cAMP Signaling
Tomas, A., Jones, B., & Leech, C. (2020) · Journal of Molecular Biology · doi:10.1016/j.jmb.2019.08.009 · Cited by 86
Erion, D. M., Park, H., & Lee, H. (2016) · BMB Reports · doi:10.5483/bmbrep.2016.49.3.268 · Cited by 100
Investigational glucagon receptor antagonists in Phase I and II clinical trials for diabetes
Scheen, A. J., Paquot, N., & Lefèbvre, P. J. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1395020 · Cited by 87
“Although the molecular mechanism is unknown, experimental findings suggest that GCGr antagonism induces increases in intestinal cholesterol absorption as this effect is neutralized by ezetimibe administration [105].”
BackgroundGlucagon's Metabolic Action in Health and Disease
Zeigerer, A., Sekar, R., Kleinert, M., Nason, S., Habegger, K. M., & Müller, T. D. (2021) · Comprehensive Physiology · doi:10.1002/cphy.c200013 · Cited by 59
The molecular pharmacology of glucagon agonists in diabetes and obesity
Novikoff, A., & Müller, T. D. (2023) · Peptides · doi:10.1016/j.peptides.2023.171003 · Cited by 82
Proglucagon-Derived Peptides as Therapeutics
Lafferty, R. A., O’Harte, F. P. M., Irwin, N., Gault, V. A., & Flatt, P. R. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.689678 · Cited by 71
Sharma, A. X., Quittner-Strom, E. B., Lee, Y., Johnson, J. A., Martin, S. A., Yu, X., Li, J., Lu, J., Cai, Z., Chen, S., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.01.065 · Cited by 71
“First-generation glucagon receptor antagonists were able to successfully lower glycemia, but they had unacceptable side effects, such as hyperlipidemia, elevated liver transaminase, and hypertension (Gu et al., 2010; Guan et al., 2015; Sammons and Lee, 2015).”
BackgroundHepatic glucagon action: beyond glucose mobilization
Kajani, S., Laker, R. C., Ratkova, E. L., Will, S., & Rhodes, C. J. (2024) · Physiological Reviews · doi:10.1152/physrev.00028.2023 · Cited by 71
Hepatic Glucagon Signaling Regulates PCSK9 and Low-Density Lipoprotein Cholesterol
Spolitu, S., Okamoto, H., Dai, W., Zadroga, J. A., Wittchen, E. S., Gromada, J., & Ozcan, L. (2019) · Circulation Research · doi:10.1161/circresaha.118.313648 · Cited by 64
Role of Glucagon and Its Receptor in the Pathogenesis of Diabetes
Jia, Y., Liu, Y., Feng, L., Sun, S., & Sun, G. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.928016 · Cited by 68
“Relevant clinical trials have shown that they can reduce blood glucose levels through inhibition of glucagon action (74–76); however, several adverse effects, such as increased LDLcholesterol (LDL-c), ALT level, and bodyweight, have been observed (74, 77).”
BackgroundPettus, J., Boeder, S. C., Christiansen, M. P., Denham, D. S., Bailey, T. S., Akturk, H. K., Klaff, L. J., Rosenstock, J., Cheng, M. H. M., Bode, B. W., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-02011-x · Cited by 54
Problem or solution: The strange story of glucagon
Scott, R. V., & Bloom, S. R. (2018) · Peptides · doi:10.1016/j.peptides.2017.11.013 · Cited by 54
“The small molecule glucagon receptor antagonists also increase LDL cholesterol, a highly undesirable side effect given the association of increased cholesterol, type 2 diabetes and cardiovascular disease [60,61,67,68]; and one, LY2409012, causes an increase in hepatic fat fraction [66].”
BackgroundGlucagon orchestrates stress‐induced hyperglycaemia
Harp, J. B., Yancopoulos, G. D., & Gromada, J. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12668 · Cited by 61
“Based on clinical trials of small-molecule glucagon receptor antagonists in patients with T2D, these agents may provide an effective alternative to insulin therapy, but with a lower incidence of hypoglycaemia and potentially reduced glucose variability [11,13,90]; however, reversible adverse effects of increased LDL c…”
BackgroundMorgan, E. S., Tai, L.-J., Pham, N. C., Overman, J. K., Watts, L. M., Smith, A., Jung, S. W., Gajdošík, M., Krššák, M., Krebs, M., et al. (2019) · Diabetes Care · doi:10.2337/dc18-1343 · Cited by 50
“Small-molecule GCGR inhibitors also increase absorption of cholesterol in the gastrointestinal tract (33), which may also explain an increase in serum lipids as well as a secondary increase in body weight.”
BackgroundKazierad, D. J., Bergman, A., Tan, B., Erion, D. M., Somayaji, V., Lee, D. S., & Rolph, T. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12672 · Cited by 44
“Indeed, results from investigation of MK-0893 in a preclinical mouse model, coupled with archived clinical samples from the 12-week study of MK-0893, suggest that glucagon receptor antagonists may increase LDL cholesterol by increasing cholesterol absorption from the gut [28].”
BackgroundCross Talk Between Insulin and Glucagon Receptor Signaling in the Hepatocyte
Habegger, K. M. (2022) · Diabetes · doi:10.2337/dbi22-0002 · Cited by 44
Insights into incretin-based therapies for treatment of diabetic dyslipidemia
Stemmer, K., Finan, B., DiMarchi, R. D., Tschöp, M. H., & Müller, T. D. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.05.008 · Cited by 43
“Opposite findings were achieved with the GCGR antagonists MK-0893 and LY2409021, both of which resulted in a significant increase in plasma LDL-C concentrations in rats [206] and humans [190], respectively.”
BackgroundGlucagon-based therapy: Past, present and future
Patil, M., Deshmukh, N., Patel, M. V., & Sangle, G. V. (2020) · Peptides · doi:10.1016/j.peptides.2020.170296 · Cited by 37
The Role of the α Cell in the Pathogenesis of Diabetes: A World beyond the Mirror
Martínez, M. S., Manzano, A., Olivar, L. C., Nava, M., Salazar, J. J., D’Marco, L., Ortíz, R., Chacín, M., Guerrero‐Wyss, M., de Bravo, M. C., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179504 · Cited by 42
“However, recent studies demonstrate that this effect is observed mainly in small molecules’ GCA, increasing cholesterol absorption in the gut [115].”
BackgroundPancreatic alpha cells and glucagon secretion: Novel functions and targets in glucose homeostasis
Wendt, A., & Eliasson, L. (2022) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2022.102199 · Cited by 37
Kostic, A., King, T. A., Yang, F., Chan, K., Yancopoulos, G. D., Gromada, J., & Harp, J. B. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13075 · Cited by 36
“Reversible increases in LDL-cholesterol and elevated serum hepatic aminotransferases levels have also been reported.(7,9,11) Modest increases in systolic and diastolic blood pressure (1.”
Hypoglycemic Effect of Combined Ghrelin and Glucagon Receptor Blockade
Mani, B. K., Uchida, A., Lee, Y., Osborne-Lawrence, S. L., Charron, M. J., Unger, R. H., Berglund, E. D., & Zigman, J. M. (2017) · Diabetes · doi:10.2337/db16-1303 · Cited by 34
Chronic fractalkine administration improves glucose tolerance and pancreatic endocrine function
Riopel, M., Seo, J. B., Bandyopadhyay, G. K., Li, P., Wollam, J., Chung, H., Jung, S., Murphy, A. N., Wilson, M. E., de Jong, R., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci94330 · Cited by 32
“Thus, the concept of targeting glucagon action to achieve hepatic insulin sensitivity and glucose lowering is well accepted (14), even though current methods of glucagon receptor inhibition may have unwanted side effects (56).”
BackgroundGlucagon resistance and metabolic-associated steatotic liver disease: a review of the evidence
McGlone, E. R., Bloom, S. R., & Tan, T. (2024) · Journal of Endocrinology · doi:10.1530/joe-23-0365 · Cited by 30
“Acute treatment with glucagon receptor antagonists is however consistently associated with an increase in liver transaminases and liver fat, which is dose-dependent and reversible on drug cessation (Guan et al. 2015, Kelly et al. 2015, Guzman et al. 2017, Kostic et al. 2018).”
BackgroundLi, H., Zhao, L., Singh, R. H., Ham, J. N., Fadoju, D., Bean, L. J., Zhang, Y., Xu, Y., Xu, H. E., & Gambello, M. J. (2018) · Molecular Genetics and Metabolism Reports · doi:10.1016/j.ymgmr.2018.09.006 · Cited by 30
Glucagon receptor signaling in metabolic diseases
Albrechtsen, N. J. W. (2018) · Peptides · doi:10.1016/j.peptides.2017.11.016 · Cited by 29
“These may chemically be divided into three groups: the small-molecule GRAs (Bay 27–9955, MK-0893 [43], MK-3577, LY-2409021 [9], PF06291874 [44], LGD-6972 [45]), the monoclonal antibodies against the GCGr (LY2786890 [46], PF-06293620, REMD-477), and thirdly the antisense oligonucleuotides against GCGr mRNA (ISIS-GCGRR…”
Kazierad, D. J., Chidsey, K., Somayaji, V. R., Bergman, A. J., & Calle, R. A. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13440 · Cited by 30
“studies may be explained by increased cholesterol absorption from the gut.(29) Furthermore, results from a recent PF-06291874 ascending”
BackgroundSmall molecule glucagon receptor antagonists: an updated patent review (2015–2019)
Cheng, C. Y., Jabri, S. Y., Taoka, B. M., & Sinz, C. J. (2020) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2020.1769600 · Cited by 28
Bergman, A. J., Tan, B., Somayaji, V. R., Calle, R. A., & Kazierad, D. J. (2017) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2017.01.019 · Cited by 26
Patel, A. R., Yusta, B., Matthews, D., Charron, M. J., Seeley, R. J., & Drucker, D. J. (2018) · Molecular Metabolism · doi:10.1016/j.molmet.2018.06.006 · Cited by 25
“The studies reported here were initiated in part to understand the potential relationship between and importance of the simultaneous elevations in BA and PGDPs observed in animal and human studies examining the metabolic consequences of genetic or pharmacological loss of GCGR signaling [7,8,11].”
BackgroundInfluentialAsadi, F., & Dhanvantari, S. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.726368 · Cited by 28
“However, blockade of the glucagon receptor may induce a-cell hyperplasia and exacerbate hyperaminoacidemia (14–16) through impairments in a liver-alpha cell axis [reviewed in (17)], and increased risk of hyperlipidemia (18).”
BackgroundSingh, S. B., Kang, L., Nawrocki, A. R., Zhou, D., Wu, M. S., Previs, S. F., Miller, C., Liu, H., Hines, C. D. G., Madeira, M., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0164133 · Cited by 23
Self-citationOptimization of Truncated Glucagon Peptides to Achieve Selective, High Potency, Full Antagonists
Yang, B. S., Gelfanov, V. M., Pérez–Tilve, D., DUBOIS, B. N., Rohlfs, R., Levy, J. J., Douros, J. D., Finan, B., Mayer, J. P., & DiMarchi, R. D. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c02069 · Cited by 22
More, V. R., Lao, J., McLaren, D. G., Cumiskey, A.-M., Murphy, B. A., Chen, Y., Previs, S., Stout, S., Patel, R., Satapati, S., et al. (2017) · PLOS ONE · doi:10.1371/journal.pone.0186586 · Cited by 21
Self-citationRegulation of Hepatic Lipid and Glucose Metabolism by INSP3R1
Perry, R. J. (2022) · Diabetes · doi:10.2337/dbi22-0003 · Cited by 20
Galsgaard, K. D., Elmelund, E., Johansen, C. D., Bomholt, A. B., Kizilkaya, H. S., Ceutz, F. R., Hunt, J. E., Kissow, H., Winther‐Sørensen, M., Sørensen, C. M., et al. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2022.101639 · Cited by 20
Structural Refinement of Glucagon for Therapeutic Use
Chabenne, J. R., Mroz, P. A., Mayer, J. P., & DiMarchi, R. D. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01493 · Cited by 19
Nunez, D. J., & D’Alessio, D. A. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13102 · Cited by 19
“type 2 diabetes, suggesting a mechanism-based association, perhaps through altered absorption of cholesterol.(58) Initially, variable data”
BackgroundBai, X., Jia, J., Kang, Q., Fu, Y., Zhou, Y., Zhong, Y., Zhang, C., & Li, M. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.605979 · Cited by 22
“Nevertheless, blockade of GCGR by antagonists was accompanied by metabolic side effects, which could potentially limit the clinical application (Guan et al., 2015; Guzman et al., 2017; Scheen et al., 2017).”
BackgroundBlockade of glucagon receptor induces α-cell hypersecretion by hyperaminoacidemia in mice
Jia, J., Bai, X., Kang, Q., Jiang, F., Wong, F. S., Jin, Q., & Li, M. (2025) · Nature Communications · doi:10.1038/s41467-025-57786-7 · Cited by 16
Gumbiner, B., Esteves, B., Dell, V., Joh, T., Garzone, P. D., Forgie, A. J., & Udata, C. (2018) · Endocrine · doi:10.1007/s12020-018-1597-1 · Cited by 14
Evidence for Glucagon Secretion and Function Within the Human Gut
Sun, E. W. L., Martin, A. M., de Fontgalland, D., Sposato, L., Rabbitt, P., Hollington, P., Wattchow, D. A., Colella, A. D., Chataway, T., Albrechtsen, N. J. W., et al. (2021) · Endocrinology · doi:10.1210/endocr/bqab022 · Cited by 13
LC–MS/MS quantification of 7α-hydroxy-4-cholesten-3-one (C4) in rat and monkey plasma
Kang, L., Connolly, T. M., Weng, N., & Jian, W. (2017) · Journal of Chromatography B · doi:10.1016/j.jchromb.2017.09.006 · Cited by 13
“discovered that glucagon receptor antagonism induced an increased cholesterol absorption [7].”
BackgroundRegulation of α‐cell glucagon secretion: The role of second messengers
Acreman, S., & Zhang, Q. (2022) · Chronic Diseases and Translational Medicine · doi:10.1016/j.cdtm.2021.06.001 · Cited by 14
Kang, Q., Hu, M., Jia, J., Bai, X., Liu, C., Wu, Z., Chen, W., & Li, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21030724 · Cited by 12
“Consistent with our results, the GCGR antagonist-treated mice induces increased liver cholesterol absorption [17].”
ResultGlucagon 100 years. Important, but still enigmatic
Holst, J. J. (2023) · Peptides · doi:10.1016/j.peptides.2023.170942 · Cited by 11
“However, the clinical studies also revealed that there was a delayed response to insulin-induced hypoglycemia; a severely increased secretion of glucagon, increased levels of LDL cholesterol; increases levels of hepatic transaminases, and increases in body weight(57).”
Shu, S., Dai, A., Wang, J., Wang, B., Feng, Y., Li, J. X., Cai, X., Yang, D., Ma, D., Wang, M., et al. (2018) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2018.02.036 · Cited by 11
Nishida, K., Ueno, S., Seino, Y., Hidaka, S., Murao, N., Asano, Y., Fujisawa, H., Shibata, M., Takayanagi, T., Ohbayashi, K., et al. (2024) · Nutrients · doi:10.3390/nu16142270 · Cited by 9
Lasher, A. T., Srivastava, H. K., & Sun, L. Y. (2022) · Biomedicines · doi:10.3390/biomedicines10081907 · Cited by 10
“Additionally, pharmacological blockade of the GCGR has been shown to decrease mRNA and protein expression of the gluconeogenic enzymes glucose-6-phosphatase and phosphoenolpyruvate carboxykinase 1 in the liver [23,28,32,34] as well as reduced activation of the key gluconeogenic transcription factor CREB [34].”
BackgroundSelf-citationKang, Q., Zheng, J., Jia, J., Xü, Y., Bai, X., Chen, X., Zhang, X.-K., Wong, F. S., Zhang, C., & Li, M. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.102665 · Cited by 7
“is usually accompanied by α-cell hyperplasia, lipid metabolism disorders, and hepatic fat accumulation (9,10).”
BackgroundHormonal Regulation of Cholesterol Homeostasis
Mao, Z., Li, J., & Zhang, W. (2018) · InTech eBooks · doi:10.5772/intechopen.76375 · Cited by 7
“This is caused by increased cholesterol absorption instead of the change in cholesterol synthesis or secretion [60].”
BackgroundGlucagon in glucose homeostasis and metabolic disease: from physiology to therapeutics
Amin, A., & Salman, T. M. (2025) · Journal of Basic and Clinical Physiology and Pharmacology · doi:10.1515/jbcpp-2025-0005 · Cited by 6
Docking and Pharmacophore Methods in Drug Discovery
Cao, Y. (2025) · ChemistrySelect · doi:10.1002/slct.202501269 · Cited by 5
iTRAQ-based quantitative proteomic analysis of Pelteobagrus vachelli liver in response to hypoxia
Wang, M., Liao, S., Fu, Z., Zang, X., Yin, S., & Wang, T. (2021) · Journal of Proteomics · doi:10.1016/j.jprot.2021.104425 · Cited by 6
Glucagon in type 1 diabetes patients receiving SGLT2 inhibitors: A Friend or Foe?
Fukui, T., Ohara, M., & Yamagishi, S. (2020) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3415 · Cited by 5
Asadi, F., Gunawardana, S. C., Dolle, R. E., & Piston, D. W. (2024) · JCI Insight · doi:10.1172/jci.insight.172626 · Cited by 4
Lafferty, R. A., Tanday, N., Dubey, V., Coulter‐Parkhill, A., Vishal, K., Moffett, R. C., O'Harte, F. P. M., Flatt, P. R., & Irwin, N. (2023) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2023.111932 · Cited by 4
Szostak, B., Kułaga, M., Kasprzak, A., Grzybek, M., Mazur-Lesińska, D., Wielgosz-Biała, S., Tyszkiewicz, K., Łozowski, B., Kasprzak, M., & Wilczyńska, B. (2025) · Prospects in Pharmaceutical Sciences · doi:10.56782/pps.361 · Cited by 3
Metabolic, enterohepatic and gut microbial effects of atorvastatin in healthy men
THOMASEN, M. L., Misiakou, M.-A., Li, S. S., de Evgrafov, M. C. R., Lynggaard, M. B., Kårhus, M. L., Brønden, A., Kornholt, J., Chávez‐Talavera, O., Tailleux, A., et al. (2026) · Endocrine Connections · doi:10.1530/ec-25-0721 · Cited by 3
“Interestingly, glucagon receptor antagonism has been shown to increase circulating levels of LDL cholesterol (47, 48), which has been linked to increased cholesterol absorption (49) and upregulation of proprotein convertase subtilisin/kexin type 9 (50).”
Min, S. H. (2024) · Journal of Korean Diabetes · doi:10.4093/jkd.2024.25.2.82 · Cited by 2
Kohnz, R. A., Zhou, D., Lou, B., Yao, H., McKenney, D., Dokwal, D., Villanueva, R., Kocalis, H. E., Ballard, J. E., Piesvaux, J., et al. (2025) · Pharmacology Research & Perspectives · doi:10.1002/prp2.70099 · Cited by 2
“…kinase (AMPK) activator [18, 19], (ii) required MoA elucidation when transitioning to clinical development, e.g., novel insulins [20, 21], or (iii) yielded unexpected outcomes while in clinical development, e.g., acetyl-CoA carboxylase (ACC) inhibitor [22], glucagon receptor antagonist [23].”
Self-citationGut-brain Axis Regulation of Food Intake and Visceral Illness
Patel, A. R. (2021) · Deep Blue (University of Michigan) · doi:10.7302/1469 · Cited by 1
Faculty Opinions recommendation of Regulation of hepatic glucose metabolism in health and disease.
Aguilar-Salinas, C. A. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.727825142.793558322
An updated patent review of small molecule glucagon receptor antagonists (2020–2024)
Wang, C., Lyu, L., Liu, D., & Yuanjia, H. (2025) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2025.2559928
“However, adverse effects, such as elevated serum aminotransferase levels, increased cholesterol or blood pressure, hyperglucago-nemia, and α-cell hyperplasia, have hindered their progression into Phase III clinical trials [22–24].”
Alterations of the glyoxylate metabolism in hepatic steatosis – a risk factor for hyperoxaluria
Jashari, A. (2020) · Technische Universität Dortmund Eldorado (Technische Universität Dortmund) · doi:10.17877/de290r-21661
Glucagon Receptor Antagonists versus Standard Care: Beta-Cell Preservation in Early Type 1 Diabetes
Latricia, M. (2026) · IAA Journal of Biological Sciences · doi:10.59298/iaajb/2026/1416064
Metadata
- Authors
- Guan, H.-P., Yang, X., Lu, K., Wang, S.-P., Castro-Perez, J. M., Previs, S., Wright, M., Shah, V., Herath, K., Xie, D., Szeto, D., Forrest, G., Xiao, J. C., Palyha, O., Sun, L.-P., Andryuk, P. J., Engel, S. S., Xiong, Y., Lin, S., Kelley, D. E., Erion, M. D., Davis, H. R., & Wang, L.
- Affiliations
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Corresponding author
- Guan, Hong-Ping
- ORCID
- Venue
- Journal of Lipid Research
- Publisher
- Elsevier BV
- Published
- 2015-11
- Volume
- 56
- Issue
- 11
- Pages
- 2183-2195
- ISSN
- 0022-2275 (ISSN-L)
- PMC
- PMC4617405
- OpenAlex
- W2179944903
- Cited by
- 76
- References
- 56
- Citations by year
- 2025: 6 · 2024: 7 · 2023: 3 · 2022: 8 · 2021: 11 · 2020: 5 · 2019: 6 · 2018: 15 · 2017: 9 · 2016: 6
- FWCI
- 10.07
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 1799 d)
- Locations
- Journal of Lipid Research (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- type 2 diabetes, LDL cholesterol elevation, cholesterol absorption, ezetimibe, glucagon-like peptide-2, cholesterol metabolism, hyperglycemia, glucose homeostasis
- MeSH terms
- Animals, Cholesterol, Diabetes Mellitus, Type 2, Drug Evaluation, Preclinical, Humans, Hypercholesterolemia, Intestinal Absorption, Male, Mice, Inbred C57BL, Mice, Transgenic, Naphthalenes, Pyrazoles, beta-Alanine, Receptors, Glucagon, Inhibitory Concentration 50
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.